Zkusit zdarma
Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

REGN
Cena:
 
 
Valuace
50
Růst
45
Zdraví
81
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

13:35 09-06-2026

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves...

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

17:38 08-06-2026

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Goldman Sachs 47th Annual Global Healthcare Confe...

Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities

Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities

2:48 08-06-2026

Regeneron Pharmaceuticals remains a "Buy," driven by EYLEA HD expansion, strong DUPIXENT growth, and...

REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics

REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics

14:25 04-06-2026

Regeneron expands its CytomX partnership to develop conditionally activated bispecific cancer therap...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

10:00 04-06-2026

NEW YORK, June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors ...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

16:32 02-06-2026

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves...

Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised)

Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised)

11:35 01-06-2026

REGN tops Q1 estimates with strong Dupixent and Eylea HD growth, but the stock slips as Eylea sales ...

Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound? (Revised)

Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound? (Revised)

11:35 01-06-2026

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock?...

Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound?

Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound?

12:31 29-05-2026

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock?...

Regeneron's Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

Regeneron's Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

16:00 28-05-2026

Inmazeb ® (a three-antibody cocktail consisting of maftivimab, atoltivimab and odesivimab-ebgn) was...

These 2 Cheap Biotech Stocks Offer Potential for Low-Beta Growth

These 2 Cheap Biotech Stocks Offer Potential for Low-Beta Growth

11:04 28-05-2026

If you're looking to diversify outside of AI, especially as AI investors look to trim their winners ...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

10:00 28-05-2026

NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors ...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

16:53 26-05-2026

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest...

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN)

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Regeneron Pharmaceuticals, Inc. (REGN)

11:31 25-05-2026

Philadelphia, Pennsylvania--(Newsfile Corp. - May 25, 2026) - Grabar Law Office is investigating cla...

Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) Over Potential Securities Fraud Allegations

Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) Over Potential Securities Fraud Allegations

0:12 25-05-2026

New York, New York--(Newsfile Corp. - May 25, 2026) - Levi & Korsinsky notifies investors that it ha...

Here's Why Regeneron (REGN) is a Strong Value Stock

Here's Why Regeneron (REGN) is a Strong Value Stock

10:41 22-05-2026

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the ...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN

18:40 21-05-2026

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors ...

Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

17:01 21-05-2026

Normalization of free light chains occurred by day 15 across all doses 100% of patients achieved a h...

Levi & Korsinsky Announces Investigation of Securities Claims Against Regeneron Pharmaceuticals, Inc. (REGN)

Levi & Korsinsky Announces Investigation of Securities Claims Against Regeneron Pharmaceuticals, Inc. (REGN)

9:00 21-05-2026

NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) lost signi...

REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud

REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud

10:00 20-05-2026

Regeneron Pharmaceuticals (NASDAQ: REGN) shares dropped sharply after the Company disclosed on May 1...

close

REGENERON ANNOUNCES INVESTOR CONFERENCE PRESENTATIONS

11-02-2026
TARRYTOWN, N.Y., FEB. 11, 2026 (GLOBE NEWSWIRE) -- REGENERON PHARMACEUTICALS, INC. (NASDAQ: REGN) W...
Více zde

REGENERON HIGHLIGHTS EXPANDING IMMUNOLOGY PORTFOLIO AND PIPELINE AT AAAAI, SHOWCASING NOVEL APPROACHES TO TREATING ALLERGY

10-02-2026
36 ABSTRACTS TO BE PRESENTED ACROSS REGENERON-INVENTED THERAPIES, INCLUDING FIRST-TIME PHASE 3 PRESE...
Více zde

EYLEA HD® (AFLIBERCEPT) INJECTION 8 MG PRESENTATIONS AT ANGIOGENESIS 2026 UNDERSCORE STRENGTH OF ITS CLINICAL PROFILE FOR THE TREATMENT OF SERIOUS RETINAL DISEASES

02-02-2026
NEW PRESENTATIONS INCLUDE FINAL 64-WEEK RESULTS FROM THE PHASE 3 QUASAR TRIAL IN PATIENTS WITH RETIN...
Více zde

REGENERON REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL AND OPERATING RESULTS

30-01-2026
TARRYTOWN, N.Y., JAN. 30, 2026 (GLOBE NEWSWIRE) -- REGENERON PHARMACEUTICALS, INC. (NASDAQ: REGN) TO...
Více zde

NATION'S TOP 40 HIGH SCHOOL SCIENTISTS TO COMPETE FOR $1.8 MILLION IN AWARDS AT THE PRESTIGIOUS REGENERON SCIENCE TALENT SEARCH

21-01-2026
SOCIETY FOR SCIENCE & REGENERON ANNOUNCED THE FINALISTS IN THE REGENERON SCIENCE TALENT SEARCH, THE ...
Více zde

DUPIXENT® (DUPILUMAB) APPROVED IN JAPAN FOR CHILDREN AGED 6 TO 11 YEARS WITH BRONCHIAL ASTHMA

23-12-2025
APPROVAL BASED ON GLOBAL PHASE 3 PROGRAM IN CHILDREN DEMONSTRATING DUPIXENT SIGNIFICANTLY REDUCED EX...
Více zde

REGENERON ANNOUNCES PRESENTATION AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

22-12-2025
TARRYTOWN, N.Y., DEC. 22, 2025 (GLOBE NEWSWIRE) -- REGENERON PHARMACEUTICALS, INC. (NASDAQ: REGN) W...
Více zde

LYNOZYFIC™ (LINVOSELTAMAB) MONOTHERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) SHOWS IMPRESSIVE RESPONSES, SUPPORTING RATIONALE AS A POTENTIAL FOUNDATION IN FRONTLINE TREATMENT

07-12-2025
ALL THREE DOSE GROUPS (50 MG, 100 MG AND 200 MG) SHOWED IMPRESSIVE MONOTHERAPY EFFICACY, WITH VGPR+ ...
Více zde

REGENERON AND TESSERA THERAPEUTICS TO JOINTLY DEVELOP TSRA-196, AN INVESTIGATIONAL GENE EDITING THERAPY FOR ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)

01-12-2025
TARRYTOWN, N.Y. AND SOMERVILLE, MASS., DEC. 01, 2025 (GLOBE NEWSWIRE) -- REGENERON PHARMACEUTICALS, ...
Více zde

PRESS RELEASE: SANOFI AND REGENERON'S DUPIXENT APPROVED AS THE FIRST TARGETED MEDICINE IN THE EU IN OVER A DECADE FOR CHRONIC SPONTANEOUS URTICARIA

25-11-2025
SANOFI AND REGENERON'S DUPIXENT APPROVED AS THE FIRST TARGETED MEDICINE IN THE EU IN OVER A DECADE F...
Více zde

EYLEA HD® (AFLIBERCEPT) INJECTION 8 MG APPROVED BY FDA FOR THE TREATMENT OF MACULAR EDEMA FOLLOWING RETINAL VEIN OCCLUSION (RVO) AND FOR MONTHLY DOSING ACROSS APPROVED INDICATIONS

19-11-2025
FIRST AND ONLY FDA-APPROVED TREATMENT  FOR RVO INDICATED FOR UP TO EVERY 8-WEEK DOSING AFTER AN INI...
Více zde

LIBTAYO® (CEMIPLIMAB) APPROVED IN THE EUROPEAN UNION AS FIRST AND ONLY IMMUNOTHERAPY FOR ADJUVANT TREATMENT OF CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) WITH HIGH RISK OF RECURRENCE AFTER SURGERY AND RADIATION

19-11-2025
APPROVAL BASED ON RESULTS OF LANDMARK PHASE 3 C-POST TRIAL THAT SHOW LIBTAYO IS FIRST IMMUNOTHERAPY ...
Více zde

REGENERON HIGHLIGHTS PROGRESS AT AMERICAN SOCIETY OF HEMATOLOGY (ASH), WITH UPDATED DATA IN MULTIPLE MYELOMA, LYMPHOMA AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PROGRAMS

13-11-2025
ORAL PRESENTATION OF LYNOZYFIC™ (LINVOSELTAMAB-GCPT) DATA IN NEWLY DIAGNOSED MULTIPLE MYELOMA FROM...
Více zde

PRESS RELEASE: ACAAI: SANOFI AND REGENERON'S DUPIXENT PIVOTAL STUDY MET ALL PRIMARY AND SECONDARY ENDPOINTS, REDUCING SIGNS AND SYMPTOMS OF ALLERGIC FUNGAL RHINOSINUSITIS; SBLA ACCEPTED FOR FDA PRIORITY REVIEW

07-11-2025
ACAAI: SANOFI AND REGENERON'S DUPIXENT PIVOTAL STUDY MET ALL PRIMARY AND SECONDARY ENDPOINTS, REDUCI...
Více zde

REGENERON ANNOUNCES INVESTOR CONFERENCE PRESENTATIONS

03-11-2025
TARRYTOWN, N.Y., NOV. 03, 2025 (GLOBE NEWSWIRE) -- REGENERON PHARMACEUTICALS, INC. (NASDAQ: REGN) W...
Více zde

DUPIXENT® (DUPILUMAB) WINS PRESTIGIOUS 2025 PRIX GALIEN USA BEST BIOTECHNOLOGY PRODUCT AWARD

31-10-2025
AWARD RECOGNIZES THE GROUNDBREAKING SCIENCE OF DUPIXENT AND ITS TRANSFORMATIONAL IMPACT ON MULTIPLE ...
Více zde

REGENERON REPORTS THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

28-10-2025
TARRYTOWN, N.Y., OCT. 28, 2025 (GLOBE NEWSWIRE) -- REGENERON PHARMACEUTICALS, INC. (NASDAQ: REGN) TO...
Více zde

LIBTAYO® (CEMIPLIMAB) RECOMMENDED FOR EU APPROVAL BY THE CHMP FOR ADJUVANT TREATMENT OF CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) WITH A HIGH RISK OF RECURRENCE AFTER SURGERY AND RADIATION

17-10-2025
POSITIVE OPINION BASED ON RESULTS OF PHASE 3 C-POST TRIAL THAT SHOW LIBTAYO SIGNIFICANTLY REDUCED TH...
Více zde

REGENERON SHOWCASES ADVANCES ACROSS ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO, HIGHLIGHTING NOVEL AND PATIENT-FOCUSED APPROACH FOR DIFFICULT-TO-TREAT CANCERS

15-10-2025
NEW SAFETY AND PHARMACOKINETIC DATA FROM PHASE 3 C-POST TRIAL PROVIDE INSIGHTS ON AN EVERY 6-WEEK DO...
Více zde

DB-OTO RESULTS IN THE NEW ENGLAND JOURNAL OF MEDICINE SHOWCASE DRAMATIC AND SUSTAINED IMPROVEMENTS IN HEARING AND SPEECH PERCEPTION IN CHILDREN WITH PROFOUND GENETIC HEARING LOSS

12-10-2025
NEARLY ALL PARTICIPANTS (11 OF 12) EXPERIENCED CLINICALLY MEANINGFUL HEARING IMPROVEMENTS, INCLUDING...
Více zde

LIBTAYO® (CEMIPLIMAB-RWLC) APPROVED IN THE U.S. AS FIRST AND ONLY IMMUNOTHERAPY FOR ADJUVANT TREATMENT OF CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) WITH A HIGH RISK OF RECURRENCE AFTER SURGERY AND RADIATION

08-10-2025
APPROVAL BASED ON PIVOTAL PHASE 3 C-POST TRIAL SHOWING LIBTAYO SIGNIFICANTLY REDUCED THE RISK OF DIS...
Více zde

REGENERON TO REPORT THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS AND HOST CONFERENCE CALL AND WEBCAST ON OCTOBER 28, 2025

30-09-2025
TARRYTOWN, N.Y., SEPT. 30, 2025 (GLOBE NEWSWIRE) -- REGENERON PHARMACEUTICALS, INC. (NASDAQ: REGN) T...
Více zde

EVKEEZA® (EVINACUMAB-DGNB) ANGPTL3 ANTIBODY APPROVED IN THE U.S. FOR CHILDREN AS YOUNG AS 1 YEAR OLD WITH ULTRA-RARE FORM OF HIGH CHOLESTEROL

26-09-2025
FDA APPROVAL EXTENDS THE INDICATION OF EVKEEZA TO TREAT YOUNGER PATIENTS WITH HOMOZYGOUS HYPERCHOLES...
Více zde

PRESS RELEASE: SANOFI AND REGENERON'S DUPIXENT TO TREAT CHRONIC SPONTANEOUS URTICARIA ADVANCES IN EU WITH POSITIVE CHMP OPINION

22-09-2025
SANOFI AND REGENERON'S DUPIXENT TO TREAT CHRONIC SPONTANEOUS URTICARIA ADVANCES IN EU WITH POSITIVE ...
Více zde

DUPIXENT® (DUPILUMAB) TO TREAT CHRONIC SPONTANEOUS URTICARIA (CSU) ADVANCES IN EU WITH POSITIVE CHMP OPINION

22-09-2025
RECOMMENDATION FOR ADULTS AND ADOLESCENTS BASED ON PHASE 3 TRIALS SHOWING DUPIXENT SIGNIFICANTLY RED...
Více zde

REGENERON DONATES EBOLA TREATMENT FOR USE IN COUNTRIES MOST AT RISK OF OUTBREAKS

19-09-2025
INMAZEB ® (ATOLTIVIMAB, MAFTIVIMAB, AND ODESIVIMAB-EBGN) WAS THE FIRST TREATMENT APPROVED BY THE U...
Více zde

REGENERON ANNOUNCES POSITIVE PHASE 3 TRIAL IN ADULTS WITH ULTRA-RARE GENETIC DISORDER FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP), DEMONSTRATING THAT GARETOSMAB PREVENTS GREATER THAN 99% OF ABNORMAL BONE FORMATION

17-09-2025
FOP IS A DISEASE IN WHICH MUSCLES, TENDONS AND LIGAMENTS ARE PROGRESSIVELY REPLACED BY BONE, LEADING...
Více zde

REGENERON ALERT: BRAGAR EAGEL & SQUIRE, P.C. IS INVESTIGATING REGENERON PHARMACEUTICALS, INC. ON BEHALF OF LONG-TERM STOCKHOLDERS AND ENCOURAGES INVESTORS TO CONTACT THE FIRM

09-09-2025
NEW YORK, SEPT. 09, 2025 (GLOBE NEWSWIRE) -- BRAGAR EAGEL & SQUIRE, P.C....
Více zde

REGENERON ANNOUNCES UPDATED PRESENTATION TIME FOR UPCOMING INVESTOR CONFERENCE

04-09-2025
TARRYTOWN, N.Y., SEPT. 04, 2025 (GLOBE NEWSWIRE) -- REGENERON PHARMACEUTICALS, INC. (NASDAQ: REGN)...
Více zde

REGENERON ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL IN GENERALIZED MYASTHENIA GRAVIS

26-08-2025
CEMDISIRAN MONOTHERAPY, DOSED SUBCUTANEOUSLY EVERY THREE MONTHS, MET THE PRIMARY AND KEY SECONDARY E...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-02-04 00:00:0010-KStáhnout
2026-01-30 00:00:008-KStáhnout
2026-01-12 00:00:008-KStáhnout
2025-10-28 00:00:008-KStáhnout
2025-10-28 00:00:0010-QStáhnout
2025-10-06 01:00:008-KStáhnout
2025-10-06 00:00:008-KStáhnout
2025-08-01 01:00:008-KStáhnout
2025-08-01 01:00:0010-QStáhnout
2025-08-01 00:00:008-KStáhnout
2025-08-01 00:00:0010-QStáhnout
2025-06-18 01:00:008-KStáhnout
2025-06-18 00:00:008-KStáhnout
2025-04-29 01:00:008-KStáhnout
2025-04-29 01:00:0010-QStáhnout
2025-04-29 00:00:008-KStáhnout
2025-04-29 00:00:0010-QStáhnout
2025-02-05 00:00:0010-KStáhnout
2025-02-04 23:00:0010-KStáhnout
2025-02-04 00:00:008-KStáhnout
2025-02-03 23:00:008-KStáhnout
2025-01-13 00:00:008-KStáhnout
2025-01-12 23:00:008-KStáhnout
2024-10-31 00:00:008-KStáhnout
2024-10-31 00:00:0010-QStáhnout
2024-10-30 23:00:008-KStáhnout
2024-10-30 23:00:0010-QStáhnout
2024-10-07 01:00:008-KStáhnout
2024-10-07 00:00:008-KStáhnout
2024-08-01 01:00:008-KStáhnout
2024-08-01 01:00:0010-QStáhnout
2024-08-01 00:00:008-KStáhnout
2024-08-01 00:00:0010-QStáhnout
2024-07-08 01:00:008-KStáhnout
2024-07-08 00:00:008-KStáhnout
2024-06-20 01:00:008-KStáhnout
2024-06-20 00:00:008-KStáhnout
2024-05-02 01:00:008-KStáhnout
2024-05-02 01:00:0010-QStáhnout
2024-05-02 00:00:008-KStáhnout
2024-05-02 00:00:0010-QStáhnout
2024-02-05 00:00:0010-KStáhnout
2024-02-04 23:00:0010-KStáhnout
2024-02-02 00:00:008-KStáhnout
2024-02-01 23:00:008-KStáhnout
2024-01-31 00:00:008-KStáhnout
2024-01-30 23:00:008-KStáhnout
2024-01-08 00:00:008-KStáhnout
2024-01-07 23:00:008-KStáhnout
2023-11-02 00:00:008-KStáhnout
2023-11-02 00:00:0010-QStáhnout
2023-11-01 23:00:008-KStáhnout
2023-11-01 23:00:0010-QStáhnout
2023-10-05 01:00:008-KStáhnout
2023-10-05 00:00:008-KStáhnout
2023-09-08 01:00:008-KStáhnout
2023-09-08 00:00:008-KStáhnout
2023-08-03 01:00:008-KStáhnout
2023-08-03 01:00:0010-QStáhnout
2023-08-03 00:00:008-KStáhnout
2023-08-03 00:00:0010-QStáhnout
2023-06-14 01:00:008-KStáhnout
2023-06-14 00:00:008-KStáhnout
2023-05-04 01:00:008-KStáhnout
2023-05-04 01:00:0010-QStáhnout
2023-05-04 00:00:008-KStáhnout
2023-05-04 00:00:0010-QStáhnout
2023-04-17 01:00:008-KStáhnout
2023-04-17 00:00:008-KStáhnout
2023-04-10 01:00:008-KStáhnout
2023-04-10 00:00:008-KStáhnout
2023-03-29 01:00:008-KStáhnout
2023-03-29 00:00:008-KStáhnout
2023-02-06 00:00:0010-KStáhnout
2023-02-05 23:00:0010-KStáhnout
2023-02-03 00:00:008-KStáhnout
2023-02-02 23:00:008-KStáhnout
2023-01-09 00:00:008-KStáhnout
2023-01-08 23:00:008-KStáhnout
2022-12-20 00:00:008-KStáhnout
2022-12-19 23:00:008-KStáhnout
2022-11-03 00:00:008-KStáhnout
2022-11-03 00:00:0010-QStáhnout
2022-11-02 23:00:008-KStáhnout
2022-11-02 23:00:0010-QStáhnout
2022-10-03 01:00:008-KStáhnout
2022-10-03 00:00:008-KStáhnout
2022-08-03 01:00:008-KStáhnout
2022-08-03 01:00:0010-QStáhnout
2022-08-03 00:00:008-KStáhnout
2022-08-03 00:00:0010-QStáhnout
2022-06-15 01:00:008-KStáhnout
2022-06-15 00:00:008-KStáhnout
2022-06-02 01:00:008-KStáhnout
2022-06-02 00:00:008-KStáhnout
2022-05-04 01:00:008-KStáhnout
2022-05-04 01:00:0010-QStáhnout
2022-05-04 00:00:008-KStáhnout
2022-05-04 00:00:0010-QStáhnout
2022-03-08 00:00:008-KStáhnout
2022-03-07 23:00:008-KStáhnout
2022-02-07 00:00:0010-KStáhnout
2022-02-06 23:00:0010-KStáhnout
2022-02-04 00:00:008-KStáhnout
2022-02-03 23:00:008-KStáhnout
2022-01-10 00:00:008-KStáhnout
2022-01-09 23:00:008-KStáhnout
2021-11-04 00:00:008-KStáhnout
2021-11-04 00:00:0010-QStáhnout
2021-11-03 23:00:008-KStáhnout
2021-11-03 23:00:0010-QStáhnout
2021-09-16 01:00:008-KStáhnout
2021-09-16 00:00:008-KStáhnout
2021-08-05 01:00:008-KStáhnout
2021-08-05 01:00:0010-QStáhnout
2021-08-05 00:00:008-KStáhnout
2021-08-05 00:00:0010-QStáhnout
2021-06-16 01:00:008-KStáhnout
2021-06-16 00:00:008-KStáhnout
2021-05-06 01:00:008-KStáhnout
2021-05-06 01:00:0010-QStáhnout
2021-05-06 00:00:008-KStáhnout
2021-05-06 00:00:0010-QStáhnout
2021-02-08 00:00:0010-KStáhnout
2021-02-07 23:00:0010-KStáhnout
2021-02-05 00:00:008-KStáhnout
2021-02-04 23:00:008-KStáhnout
2021-01-15 00:00:008-KStáhnout
2021-01-14 23:00:008-KStáhnout
2021-01-11 00:00:008-KStáhnout
2021-01-10 23:00:008-KStáhnout
2021-01-05 00:00:008-KStáhnout
2021-01-04 23:00:008-KStáhnout
2020-11-05 00:00:008-KStáhnout
2020-11-05 00:00:0010-QStáhnout
2020-11-04 23:00:008-KStáhnout
2020-11-04 23:00:0010-QStáhnout
2020-08-19 01:00:008-KStáhnout
2020-08-19 00:00:008-KStáhnout
2020-08-12 01:00:008-KStáhnout
2020-08-12 00:00:008-KStáhnout
2020-08-05 01:00:008-KStáhnout
2020-08-05 01:00:0010-QStáhnout
2020-08-05 00:00:008-KStáhnout
2020-08-05 00:00:0010-QStáhnout
2020-07-07 01:00:008-KStáhnout
2020-07-07 00:00:008-KStáhnout
2020-06-16 01:00:008-KStáhnout
2020-06-16 00:00:008-KStáhnout
2020-05-29 01:00:008-KStáhnout
2020-05-29 00:00:008-KStáhnout
2020-05-05 01:00:008-KStáhnout
2020-05-05 01:00:0010-QStáhnout
2020-05-05 00:00:008-KStáhnout
2020-05-05 00:00:0010-QStáhnout
2020-04-07 01:00:008-KStáhnout
2020-04-07 00:00:008-KStáhnout
2020-02-07 00:00:0010-KStáhnout
2020-02-06 23:00:0010-KStáhnout
2020-02-06 00:00:008-KStáhnout
2020-02-05 23:00:008-KStáhnout
2020-01-13 00:00:008-KStáhnout
2020-01-12 23:00:008-KStáhnout
2019-11-05 00:00:008-KStáhnout
2019-11-05 00:00:0010-QStáhnout
2019-11-04 23:00:008-KStáhnout
2019-11-04 23:00:0010-QStáhnout
2019-08-06 01:00:008-KStáhnout
2019-08-06 01:00:0010-QStáhnout
2019-08-06 00:00:008-KStáhnout
2019-08-06 00:00:0010-QStáhnout
2019-06-19 01:00:008-KStáhnout
2019-06-19 00:00:008-KStáhnout
2019-05-07 01:00:008-KStáhnout
2019-05-07 01:00:0010-QStáhnout
2019-05-07 00:00:008-KStáhnout
2019-05-07 00:00:0010-QStáhnout
2019-05-03 01:00:008-KStáhnout
2019-05-03 00:00:008-KStáhnout
2019-04-10 01:00:008-KStáhnout
2019-04-10 00:00:008-KStáhnout
2019-02-07 00:00:0010-KStáhnout
2019-02-06 23:00:0010-KStáhnout
2019-02-06 00:00:008-KStáhnout
2019-02-05 23:00:008-KStáhnout
2019-01-07 00:00:008-KStáhnout
2019-01-06 23:00:008-KStáhnout
2018-12-17 00:00:008-KStáhnout
2018-12-16 23:00:008-KStáhnout
2018-11-06 00:00:008-KStáhnout
2018-11-06 00:00:0010-QStáhnout
2018-11-05 23:00:008-KStáhnout
2018-11-05 23:00:0010-QStáhnout
2018-10-12 01:00:008-KStáhnout
2018-10-12 00:00:008-KStáhnout
2018-08-02 01:00:008-KStáhnout
2018-08-02 01:00:0010-QStáhnout
2018-08-02 00:00:008-KStáhnout
2018-08-02 00:00:0010-QStáhnout
2018-06-13 01:00:008-KStáhnout
2018-06-13 00:00:008-KStáhnout
2018-05-03 01:00:008-KStáhnout
2018-05-03 01:00:0010-QStáhnout
2018-05-03 00:00:008-KStáhnout
2018-05-03 00:00:0010-QStáhnout
2018-02-08 00:00:008-KStáhnout
2018-02-08 00:00:0010-KStáhnout
2018-02-07 23:00:008-KStáhnout
2018-02-07 23:00:0010-KStáhnout
2018-01-18 00:00:008-KStáhnout
2018-01-17 23:00:008-KStáhnout
2018-01-08 00:00:008-KStáhnout
2018-01-07 23:00:008-KStáhnout
2018-01-02 00:00:008-KStáhnout
2018-01-01 23:00:008-KStáhnout
2017-11-08 00:00:008-KStáhnout
2017-11-08 00:00:0010-QStáhnout
2017-11-07 23:00:008-KStáhnout
2017-11-07 23:00:0010-QStáhnout
2017-08-03 01:00:008-KStáhnout
2017-08-03 01:00:0010-QStáhnout
2017-08-03 00:00:008-KStáhnout
2017-08-03 00:00:0010-QStáhnout
2017-06-14 01:00:008-KStáhnout
2017-06-14 00:00:008-KStáhnout
2017-05-04 01:00:008-KStáhnout
2017-05-04 01:00:0010-QStáhnout
2017-05-04 00:00:008-KStáhnout
2017-05-04 00:00:0010-QStáhnout
2017-03-09 00:00:008-KStáhnout
2017-03-08 23:00:008-KStáhnout
2017-02-09 00:00:008-KStáhnout
2017-02-09 00:00:0010-KStáhnout
2017-02-08 23:00:008-KStáhnout
2017-02-08 23:00:0010-KStáhnout
2017-02-07 00:00:008-KStáhnout
2017-02-06 23:00:008-KStáhnout
2017-01-31 00:00:008-KStáhnout
2017-01-30 23:00:008-KStáhnout
2017-01-09 00:00:008-KStáhnout
2017-01-08 23:00:008-KStáhnout
2016-12-30 00:00:008-KStáhnout
2016-12-29 23:00:008-KStáhnout
2016-12-21 00:00:008-KStáhnout
2016-12-20 23:00:008-KStáhnout
2016-11-25 00:00:008-KStáhnout
2016-11-24 23:00:008-KStáhnout
2016-11-18 00:00:008-KStáhnout
2016-11-17 23:00:008-KStáhnout
2016-11-14 00:00:008-KStáhnout
2016-11-13 23:00:008-KStáhnout
2016-11-04 00:00:008-KStáhnout
2016-11-04 00:00:0010-QStáhnout
2016-11-03 23:00:008-KStáhnout
2016-11-03 23:00:0010-QStáhnout
2016-10-28 01:00:008-KStáhnout
2016-10-28 00:00:008-KStáhnout
2016-09-20 01:00:008-KStáhnout
2016-09-20 00:00:008-KStáhnout
2016-09-14 01:00:008-KStáhnout
2016-09-14 00:00:008-KStáhnout
2016-08-04 01:00:008-KStáhnout
2016-08-04 01:00:0010-QStáhnout
2016-08-04 00:00:008-KStáhnout
2016-08-04 00:00:0010-QStáhnout
2016-06-15 01:00:008-KStáhnout
2016-06-15 00:00:008-KStáhnout
2016-05-05 01:00:008-KStáhnout
2016-05-05 01:00:0010-QStáhnout
2016-05-05 00:00:008-KStáhnout
2016-05-05 00:00:0010-QStáhnout
2016-03-29 01:00:008-KStáhnout
2016-03-29 00:00:008-KStáhnout
2016-02-24 00:00:008-KStáhnout
2016-02-23 23:00:008-KStáhnout
2016-02-19 00:00:008-KStáhnout
2016-02-18 23:00:008-KStáhnout
2016-02-11 00:00:0010-KStáhnout
2016-02-10 23:00:0010-KStáhnout
2016-02-09 00:00:008-KStáhnout
2016-02-08 23:00:008-KStáhnout
2016-02-02 00:00:008-KStáhnout
2016-02-01 23:00:008-KStáhnout
2016-01-12 00:00:008-KStáhnout
2016-01-11 23:00:008-KStáhnout
2015-11-19 00:00:008-KStáhnout
2015-11-18 23:00:008-KStáhnout
2015-11-16 00:00:008-KStáhnout
2015-11-15 23:00:008-KStáhnout
2015-11-13 00:00:008-KStáhnout
2015-11-12 23:00:008-KStáhnout
2015-11-04 00:00:008-KStáhnout
2015-11-04 00:00:0010-QStáhnout
2015-11-03 23:00:008-KStáhnout
2015-11-03 23:00:0010-QStáhnout
2015-10-02 01:00:008-KStáhnout
2015-10-02 00:00:008-KStáhnout
2015-08-06 01:00:008-KStáhnout
2015-08-06 00:00:008-KStáhnout
2015-08-04 01:00:008-KStáhnout
2015-08-04 01:00:0010-QStáhnout
2015-08-04 00:00:008-KStáhnout
2015-08-04 00:00:0010-QStáhnout
2015-07-31 01:00:008-KStáhnout
2015-07-31 00:00:008-KStáhnout
2015-06-17 01:00:008-KStáhnout
2015-06-17 00:00:008-KStáhnout
2015-05-07 01:00:008-KStáhnout
2015-05-07 01:00:0010-QStáhnout
2015-05-07 00:00:008-KStáhnout
2015-05-07 00:00:0010-QStáhnout
2015-03-23 00:00:008-KStáhnout
2015-03-22 23:00:008-KStáhnout
2015-03-16 00:00:008-KStáhnout
2015-03-15 23:00:008-KStáhnout
2015-03-05 00:00:008-KStáhnout
2015-03-04 23:00:008-KStáhnout
2015-02-27 00:00:008-KStáhnout
2015-02-26 23:00:008-KStáhnout
2015-02-12 00:00:0010-KStáhnout
2015-02-11 23:00:0010-KStáhnout
2015-02-10 00:00:008-KStáhnout
2015-02-09 23:00:008-KStáhnout
2015-01-12 23:00:008-KStáhnout
2014-12-21 23:00:008-KStáhnout
2014-11-25 23:00:008-KStáhnout
2014-11-20 23:00:008-KStáhnout
preloader